상세 가이드 곧 제공 예정
Oxygen Therapy Target Calculator에 대한 종합 교육 가이드를 준비 중입니다. 단계별 설명, 공식, 실제 예제 및 전문가 팁을 곧 확인하세요.
Supplemental oxygen therapy is one of the most widely used and critically important treatments in medicine, yet its administration requires careful titration to achieve target oxygen saturations (SpO2) without causing harm from either hypoxaemia or hyperoxaemia. The NIH and major international guidelines provide specific SpO2 target ranges for different patient populations, recognising that giving too much oxygen can be as harmful as giving too little. For most acutely unwell adults, the target SpO2 is 94–98% (British Thoracic Society and WHO) — a range that ensures adequate tissue oxygenation without causing absorption atelectasis, oxygen-free radical damage, or suppression of hypoxic ventilatory drive. For patients at risk of hypercapnic respiratory failure — predominantly those with COPD, severe obesity-hypoventilation, bronchiectasis, or neuromuscular disease with hypercapnia — the target SpO2 is lower: 88–92%. This is because these patients have chronic CO2 retention and depend partly on hypoxic drive to breathe; normalising their oxygen saturation can suppress their ventilatory drive and worsen CO2 retention, precipitating life-threatening hypercapnic acidosis. Neonates have a target of 91–95% to balance adequate oxygenation against the risk of retinopathy of prematurity from high oxygen exposure. The BTS/NIH guidance emphasises SpO2-guided oxygen titration using pulse oximetry rather than fixed-flow oxygen delivery, and randomised trials have shown that this approach reduces 30-day mortality compared to high-flow liberal oxygen in non-hypoxaemic patients. Venturi masks allow precise FiO2 delivery in COPD patients (24%, 28%, 35%, 40%, 60% FiO2) and are preferred over simple face masks for accurate titration.
Target SpO2: COPD/hypercapnic risk = 88–92%; Most adults = 94–98%; Neonates = 91–95%; FiO2 via Venturi mask: colour-coded 24–60%
- 1Assess the patient's risk of hypercapnic respiratory failure: COPD (especially severe, with known prior hypercapnia), obesity-hypoventilation, severe kyphoscoliosis, neuromuscular disease, or prior NIV use suggests hypercapnic risk.
- 2Set target SpO2: 88–92% for hypercapnic risk patients; 94–98% for all other adults.
- 3Select oxygen delivery device based on flow requirement: nasal cannulae 1–6 L/min (FiO2 24–44%); simple face mask 5–10 L/min (FiO2 35–60%); Venturi mask 2–15 L/min (precise FiO2 24–60%); high-flow nasal oxygen (HFNO) 10–60 L/min (FiO2 up to 100%).
- 4Titrate oxygen flow to maintain SpO2 within target range — reduce flow if SpO2 persistently above upper target; increase if below lower target.
- 5For COPD patients, use Venturi mask (not simple face mask) to deliver precise, controlled FiO2 — start at 28% and titrate.
- 6Check ABG in patients with COPD or hypercapnic risk within 30–60 minutes of oxygen initiation to confirm PaCO2 is not rising.
- 7In acutely critically unwell patients (cardiac arrest, shock, major trauma), give 100% oxygen initially via non-rebreather mask until stabilised, then titrate to target range.
High-flow or uncontrolled oxygen in COPD exacerbation can precipitate hypercapnic coma
COPD with hypercapnia requires controlled low-flow oxygen targeting 88–92% SpO2. Monitor ABG closely for CO2 retention worsening.
Do not give high-flow O2 routinely — target 94–98% and stop when SpO2 consistently at target on room air
A patient without hypercapnic risk who is hypoxaemic post-operatively needs supplemental O2 to reach 94–98%, but does not need 100% O2.
AVOID O2 DETO trial and ILCOR 2015 guidance: oxygen harmful in normoxaemic ACS
Randomised trials (AVOID, DETO2X) showed that giving supplemental oxygen to normoxaemic MI patients increases myocardial injury. Oxygen should only be given if SpO2 <94%.
SpO2 >95% in premature neonates increases risk of retinopathy of prematurity (ROP) and BPD
Premature neonatal retinal blood vessels are highly sensitive to hyperoxia, which causes vasoconstriction and subsequent neovascularisation (ROP). The lower SpO2 target (91–95%) balances oxygenation against ROP risk.
Acute management of hypoxaemia in any setting (emergency department, ward, ICU) using target SpO2 to guide titration., representing an important application area for the Nih Oxygen Therapy in professional and analytical contexts where accurate nih oxygen therapy calculations directly support informed decision-making, strategic planning, and performance optimization
COPD exacerbation management: controlled 28–35% Venturi oxygen to achieve SpO2 88–92% while monitoring for CO2 retention., representing an important application area for the Nih Oxygen Therapy in professional and analytical contexts where accurate nih oxygen therapy calculations directly support informed decision-making, strategic planning, and performance optimization
Post-operative monitoring and oxygen weaning in recovery rooms after general anaesthesia., representing an important application area for the Nih Oxygen Therapy in professional and analytical contexts where accurate nih oxygen therapy calculations directly support informed decision-making, strategic planning, and performance optimization
Long-term oxygen therapy (LTOT) prescribing for stable COPD with resting PaO2 ≤7.3 kPa on ABG., representing an important application area for the Nih Oxygen Therapy in professional and analytical contexts where accurate nih oxygen therapy calculations directly support informed decision-making, strategic planning, and performance optimization
Neonatal intensive care: titrating incubator or nasal CPAP oxygen to 91–95% SpO2 in premature infants to prevent retinopathy of prematurity., representing an important application area for the Nih Oxygen Therapy in professional and analytical contexts where accurate nih oxygen therapy calculations directly support informed decision-making, strategic planning, and performance optimization
Oxygen in Stroke
{'title': 'Oxygen in Stroke', 'body': 'Routine supplemental oxygen in normoxaemic acute stroke patients is harmful — the SO2 (Stroke Oxygen Supplementation) trial showed that giving nocturnal oxygen to normoxaemic stroke patients increased 3-month mortality. Oxygen should only be given to stroke patients with SpO2 <94% (or <88–92% if hypercapnic risk). This is a common area of unnecessary oxygen prescribing in clinical practice.'}
Oxygen in Palliative Care
{'title': 'Oxygen in Palliative Care', 'body': 'Supplemental oxygen does not relieve dyspnoea in non-hypoxaemic patients with terminal illness — this has been demonstrated in multiple RCTs including the Booth trial. Cool airflow to the face (fan therapy) is more effective for dyspnoea in normoxaemic palliative patients. Oxygen should only be given for comfort if the patient is hypoxaemic (SpO2 <88%) or expresses a strong preference for it.'}
Obesity-Hypoventilation Syndrome
{'title': 'Obesity-Hypoventilation Syndrome', 'body': 'Patients with obesity-hypoventilation syndrome (OHS, defined as BMI >30 + daytime PaCO2 >6 kPa without other cause) should be treated as hypercapnic risk patients with a target SpO2 of 88–92%. Many OHS patients are undiagnosed — any severely obese patient with unexplained hypercapnia should have oxygen prescribed cautiously, and NIV should be strongly considered.'}
Oxygen During Transport
{'title': 'Oxygen During Transport', 'body': "During transfer of critically ill patients, oxygen must be carefully monitored and target SpO2 maintained. Commercial air travel (cabin pressure equivalent to 6,000–8,000 feet altitude) reduces SpO2 by approximately 4% in healthy individuals — patients with baseline SpO2 below 94% at sea level should have an aviation medical assessment and may require in-flight supplemental oxygen via the airline's medical oxygen system."}
| Patient Group | SpO2 Target | Preferred Device | Notes |
|---|---|---|---|
| Most acutely unwell adults | 94–98% | Nasal cannulae or simple face mask | Titrate to target; avoid hyperoxia |
| COPD / hypercapnic risk | 88–92% | Venturi mask (28% start) | Check ABG within 30–60 min |
| Premature neonates (<37 wk) | 91–95% | Incubator O2 or nasal CPAP | Monitor for ROP |
| Term neonates and infants | 94–98% | Nasal cannulae | As per adult targets |
| CO poisoning | 100% (non-rebreather) | Tight-fitting non-rebreather mask | SpO2 unreliable; 100% O2 always |
| Normoxaemic ACS (SpO2 ≥94%) | Do not supplement | Room air | Oxygen harmful in normoxaemic MI |
Why does giving too much oxygen harm COPD patients?
COPD patients with chronic hypercapnia have adapted to high CO2 levels. Traditionally, the 'hypoxic drive' theory held that their breathing was driven by low oxygen. More recent evidence suggests multiple mechanisms: the Haldane effect (high O2 displaces CO2 from haemoglobin, raising PaCO2), V/Q mismatch redistribution (oxygen causes vasodilation in poorly ventilated areas, worsening V/Q mismatch), and some contribution from reduced hypoxic drive. Whatever the mechanism, liberal oxygen in COPD with hypercapnia worsens CO2 retention and can cause respiratory acidosis.
What is the difference between SpO2 and SaO2?
SpO2 is peripheral oxygen saturation measured non-invasively by pulse oximetry using light absorption. SaO2 is arterial oxygen saturation measured directly from an arterial blood gas sample. In most situations, SpO2 and SaO2 correlate well (within 2–3%), but SpO2 can be inaccurate in: poor peripheral perfusion (cold, shock, vasoconstriction), dark skin pigmentation (may overestimate SpO2 by 2–4%), nail polish, methaemoglobinaemia, and carboxyhaemoglobinaemia (CO poisoning — SpO2 reads falsely normal even when actual SaO2 is very low).
What is high-flow nasal oxygen (HFNO) and when is it used?
HFNO (e.g., Optiflow system) delivers heated, humidified oxygen at flows of 10–60 L/min through a wide-bore nasal cannula, achieving FiO2 up to 100% and generating a small amount of PEEP (2–3 cmH2O). It is used for hypoxaemic respiratory failure, post-extubation, and some COPD exacerbations (though NIV is generally preferred for COPD with hypercapnia). HFNO improves oxygenation, reduces breathing effort, and is more comfortable than face masks for prolonged use.
What is the Venturi mask and how does it work?
A Venturi (or air-entrainment) mask uses the Bernoulli principle: high-pressure oxygen flowing through a narrow jet entrains room air in a fixed ratio, delivering a precise, controlled FiO2 regardless of the patient's breathing pattern or flow rate. Colour-coded Venturi valves deliver 24%, 28%, 35%, 40%, and 60% FiO2. This precision makes Venturi masks the preferred device for COPD patients where controlled FiO2 is essential.
When should oxygen therapy be stopped?
Supplemental oxygen should be weaned and stopped when the patient maintains SpO2 within target range on room air during rest and, where applicable, during mild exertion. Continuing oxygen unnecessarily (particularly high-flow oxygen in non-hypoxaemic patients) risks oxygen toxicity (alveolar damage from reactive oxygen species), absorption atelectasis, and suppression of hypoxic pulmonary vasoconstriction. Check SpO2 on room air at each clinical review.
What is the BTS emergency oxygen guideline?
The British Thoracic Society Emergency Oxygen guideline (2017) recommends: (1) prescribe oxygen on the drug chart like any other medication, including target SpO2 range; (2) use 94–98% target for most patients; (3) use 88–92% for patients at risk of hypercapnic respiratory failure; (4) never prescribe '100% oxygen' or 'high-flow O2' without specifying target SpO2; (5) reassess SpO2 and ABG regularly during acute illness.
Can oxygen be given in carbon monoxide poisoning?
Yes — 100% oxygen via tight-fitting non-rebreather mask is the immediate treatment for CO poisoning and one of the situations where high-flow O2 is always indicated regardless of SpO2 (which reads falsely normal with standard pulse oximetry). 100% O2 reduces the half-life of carboxyhaemoglobin from approximately 5 hours (on room air) to 60–90 minutes. Hyperbaric oxygen further reduces this to 20–30 minutes and is considered in severe poisoning.
What is oxygen toxicity and when does it occur?
Oxygen toxicity from prolonged exposure to high FiO2 (>60%) causes alveolar damage mediated by reactive oxygen species. In the lung, it causes a condition resembling ARDS: alveolar flooding, hyaline membrane formation, and diffuse alveolar damage. Clinical oxygen toxicity occurs with FiO2 >60% for more than 24–48 hours. It is largely avoided by titrating oxygen to target SpO2 and using the minimum FiO2 required.
전문가 팁
Think of oxygen as a drug: prescribe it with a specific target SpO2, document the rationale, and review at every clinical assessment. The BTS Emergency Oxygen Guideline recommends using pre-printed prescription labels or oxygen prescription fields in drug charts to standardise practice and prevent prescribing errors.
알고 계셨나요?
Long-term oxygen therapy (LTOT) was first shown to extend survival in hypoxaemic COPD patients in two landmark trials published simultaneously in 1980 — the UK MRC study and the US NOTT (Nocturnal Oxygen Therapy Trial). These trials demonstrated that oxygen given ≥15 hours/day significantly reduced mortality in COPD patients with PaO2 <7.3 kPa, establishing LTOT as one of only two interventions (along with smoking cessation) that improved survival in COPD.
참고 자료
- ›BTS Guideline — Emergency Oxygen Use in Adult Patients (2017)
- ›Siemieniuk RAC et al — O2 Therapy for Acutely Ill Adults: Systematic Review (BMJ 2018)
- ›Stub D et al — AVOID Trial — O2 in MI (Circulation 2015)
- ›MRC Working Party — Long-Term Domiciliary O2 Therapy in COPD (Lancet 1981)
- ›WHO — Oxygen Therapy for Children (2016)